GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (OTCPK:GRTSQ) » Definitions » Cash Ratio

GRTSQ (Gritstone Bio) Cash Ratio : 2.33 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Gritstone Bio's Cash Ratio for the quarter that ended in Jun. 2024 was 2.33.

Gritstone Bio has a Cash Ratio of 2.33. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Gritstone Bio's Cash Ratio or its related term are showing as below:

GRTSQ' s Cash Ratio Range Over the Past 10 Years
Min: 1.79   Med: 5.64   Max: 15.04
Current: 2.33

During the past 8 years, Gritstone Bio's highest Cash Ratio was 15.04. The lowest was 1.79. And the median was 5.64.

GRTSQ's Cash Ratio is ranked worse than
54.14% of 1474 companies
in the Biotechnology industry
Industry Median: 2.665 vs GRTSQ: 2.33

Gritstone Bio Cash Ratio Historical Data

The historical data trend for Gritstone Bio's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Cash Ratio Chart

Gritstone Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 6.55 6.34 5.05 4.94 2.90

Gritstone Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.18 3.59 2.90 1.79 2.33

Competitive Comparison of Gritstone Bio's Cash Ratio

For the Biotechnology subindustry, Gritstone Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gritstone Bio's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's Cash Ratio falls into.



Gritstone Bio Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Gritstone Bio's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=79.274/27.339
=2.90

Gritstone Bio's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=55.712/23.901
=2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gritstone Bio  (OTCPK:GRTSQ) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Gritstone Bio Cash Ratio Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gritstone Bio Business Description

Traded in Other Exchanges
Address
5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.
Executives
Andrew R Allen director, officer: President and CEO 2525 28TH STREET, SUITE 200, BOULDER CO 80301
Matthew Hawryluk officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Erin Jones officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Vassiliki Economides officer: See Remarks C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Jooss officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Lawrence Corey director C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi director C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher director C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James Cho officer: Chief Accounting Officer C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104